To clot, or not to clot – Antithrombotic therapy is the question

South African Family Practice

Field Value
Title To clot, or not to clot – Antithrombotic therapy is the question
Creator Osuch, E. Marais, A.
Subject — anticoagulant; antiplatelet; direct oral anticoagulants (DOACs); haemostasis; thromboembolism; thrombolytic therapy; vitamin K antagonists
Description Haemostasis and thrombosis rely on three components namely the vascular endothelial wall, blood platelets and the coagulation cascade. Non-physiologic excessive thrombosis occurs when haemostatic processes are dysfunctional, causing undue clot formation or reduced clot lysis. Antithrombotic agents including antiplatelet, anticoagulation and fibrinolytic agents are essential for the prophylaxis and pharmacological management of venous thromboembolism and arterial thrombosis. Anticoagulation treatment options have expanded steadily over the past few decades, providing a greater number of agents. Anticoagulants that directly target the enzymatic activity of thrombin and factor Xa have recently been developed to address the inadequacies of traditional vitamin K antagonists. Appropriate use of these agents requires knowledge of their individual characteristics, risks, and benefits.
Publisher AOSIS
Date 2019-07-15
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Peer-reviewed Article —
Format application/pdf
Identifier 10.4102/safp.v61i3.4966
Source South African Family Practice; Vol 61, No 3 (2019): May/June; 32-40 2078-6204 2078-6190
Language eng
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:
Coverage — — —
Rights Copyright (c) 2019 E. Osuch, A. Marais